June 24, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib (Ibrance, Pfizer) was approved in combination with trastuzumab (Herceptin, Genentech), with or without pertuzumab (Perjeta, Genetech), and endocrine therapy as maintenance treatment for adults with HR-positive,
509 words~2 min read
